News

Sickle cell disease (SCD) is the most common inherited clinically significant blood disorder, affecting at least 100 000 Americans and millions around the world.…

The approval expands the use of Casgevy to patients as young as 2 years old for the treatment of sickle cell disease and| beta thalassemiaThe USFDA issued a…

The U.S. Food and Drug Administration today issued a supplemental approval for Casgevy (exagamglogene autotemcel) for patients aged 2 years and older with either…

First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia --…

A low dose of Vascarta‘s VAS-101, a curcumin-based gel being developed for sickle cell disease (SCD), was well tolerated and showed early signs of reducing red…

For adults with sickle cell disease (SCD), a cost-effectiveness analysis suggests that treatment with nonmyeloablative haploidentical (NMAC-HID) allogeneic stem…

June 19 is the annual date the world marks ‘International  Sickle Cell Day’. The theme for this year’s own is, “Closing the Survival Gap: Equity in Sickle Cell…

The first patient with sickle cell disease (SCD) treated with the base-editing therapy CS-206 in China remained free of vaso-occlusive crises for over 15…

Daniel Cressy became the first person in the Gulf South to be functionally cured of sickle cell disease through gene editing. Calling it his "second birthday," he…

Children with sickle cell anemia, the most common and severe form of sickle cell disease (SCD), who undergo stem cell transplant experience better long-term…